KPV

KPV Capsules is supplied by Crystal Peptides as a catalogued research material in capsules, 500mcg per capsule, 60 capsules. This presentation identifies the catalogue format and declared content; batch-specific analytical documentation should be consulted separately when assessing material identity, composition and suitability for a defined laboratory investigation.

KPV is the Lys-Pro-Val tripeptide corresponding to the C-terminal sequence of alpha-Melanocyte-Stimulating Hormone (alpha-MSH). Sequence origin does not establish chemical equivalence to the parent hormone. Free-acid KPV, amidated KPV and materials with different salts or counter-ions are distinct exact forms. The termini and material form of this product must be confirmed from batch documentation rather than inferred from its catalogue name.

Chemical properties and registry information

Registry assignments are molecular-entity-specific and do not describe the complete capsule formulation. Batch records take precedence over identifiers associated with related peptide forms.

Research background and published evidence

Published research

KPV has been examined in preclinical cell and mouse models addressing inflammatory signalling, epithelial responses and intestinal-barrier biology. Published work provides a context for investigating peptide-associated changes in experimental endpoints, rather than evidence for this catalogue presentation. Interpretation depends on the exact peptide form, experimental model, matrix, exposure conditions and analytical methods used.

Current scientific understanding

The relevant evidence remains preclinical and model-dependent. Inflammatory-signalling measurements and intestinal-barrier endpoints describe different aspects of experimental biology and should not be treated as interchangeable findings. Results involving full-length alpha-MSH, amidated KPV or other related materials require direct comparability before being applied to a different chemical form. These studies neither authenticate this batch nor establish human or veterinary outcomes.

Formulation note

Published research has mostly used materials, experimental preparations or routes other than this capsule presentation. Findings from injected or differently formulated material cannot be transferred to this capsules formulation. Capsule composition introduces a distinct experimental matrix, and nominal peptide content alone does not establish equivalence to a published preparation. Any comparison requires formulation-specific evidence addressing peptide identity, content and matrix effects.

Quality and testing

Quality information must be tied to the batch-specific Certificate of Analysis (CoA) for this exact capsule product. Reports for another lot, pack size or presentation are not evidence for the supplied material. Verify the correspondence between the product label, lot identifier, CoA and SDS before relying on reported specifications.

Identity, chromatographic area purity, peptide content and capsule composition are separate analytical questions. A purity result does not establish declared content or consistency between capsules. Only measurements documented in a matching batch report should be regarded as available; absent results must not be inferred from catalogue terminology or literature descriptions.

For laboratory research use only by qualified professionals. Not for human or veterinary use. No dosing directions are provided.